COVAXX

COVAXX, also known as C19 Corp. and C19 Corporation,^[1] is an American biotechnology company based in Hauppauge, New York. It was previously a division of United Biomedical^[2] and is now a subsidiary of Vaxxinity.^[3] It is developing a "multitope protein/peptide-based" COVID-19 vaccine candidate called UB-612, with phase 2 clinical trials taking place at the University of Nebraska Medical Center.^[3:1]